MedTrace Logo

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

NCT03774056 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2020-11-03

No results posted yet for this study

Summary

This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of HC-1119 in patients with metastatic castration-resistant prostate cancer. The study objective is to study the tolerability, safety, and dose-limiting toxicities (DLT) of HC-1119 in patients with mCRPC.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

HC-1119

oral

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • Hinova Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Feng Bi, professor · West China Hospital

  • Li Zheng, professor · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-10
Primary Completion
2018-09-26
Completion
2019-08-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03774056 on ClinicalTrials.gov